SEARCH:   Advanced

Blood, 1 September 2004, Vol. 104, No. 5, pp. 1435-1441. Prepublished online as a Blood First Edition Paper on May 13, 2004; DOI 10.1182/blood-2003-12-4306. This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 2003-12-4306v1 104/5/1435    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zaza, G. Articles by Evans, W. E. Search for Related Content PubMed PubMed Citation Articles by Zaza, G. Articles by Evans, W. E. Related Collections Neoplasia Oncogenes and Tumor Suppressors Signal Transduction Gene Expression Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis Gianluigi Zaza, Wenjian Yang, Leo Kager, Meyling Cheok, James Downing, Ching-Hon Pui, Cheng Cheng, Mary V. Relling, and William E. Evans From the Departments of Pharmaceutical Sciences, Pathology, Hematology-Oncology, and Biostatistics, St Jude Children's Research Hospital, Memphis, TN; the University of Tennessee, Memphis; and University of Bari, Italy. Because de novo purine synthesis (DNPS) is a target of widely used antileukemic agents (eg, methotrexate, mercaptopurine), we determined the rate of DNPS and the expression of genes involved in purine metabolism in different subtypes of acute lymphoblastic leukemia (ALL). Among 113 children with newly diagnosed ALL, lymphoblasts with the TEL-AML1 translocation had significantly lower DNPS than all other genetic subtypes of B-lineage ALL or T-lineage ALL (352 ± 57 versus 1001 ± 31 or versus 1315 ± 76 fmol/nmol/h, P < .0001). By assessing the expression of 82 genes involved in purine metabolism (KEGG pathway database) in ALL blasts from 38 patients with B-lineage ALL (14 with TEL-AML1, 24 without), we identified 16 genes that were differentially expressed in TEL-AML1–positive and TEL-AML1–negative ALL (P < .001, false discovery rate [FDR] = 5%). The pattern of expression of these 16 genes discriminated TEL-AML1–positive ALL with a true accuracy of 84% in an independent test set (n = 17, confidence interval 70% to 94%, P < .001). Western blots of selected genes documented corresponding levels of the proteins encoded. Differentially expressed genes included HPRT, IMPDH, PAICS, and GART, all of which were expressed at a significantly lower level in TEL-AML1 ALL. These findings have established that TEL-AML1 ALL has significantly lower de novo purine synthesis and differential expression of genes involved in purine metabolism. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Targeting ALL leukemia Jerald P. Radich Blood 2004 104: 1235-1236. [Full Text] [PDF] This article has been cited by other articles: A. Andersson, T. Olofsson, D. Lindgren, B. Nilsson, C. Ritz, P. Eden, C. Lassen, J. Rade, M. Fontes, H. Morse, et al. Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations PNAS, December 27, 2005; 102(52): 19069 - 19074. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020